The Vaccine Alliance (Gavi) is co-piloting with the World Health Organization (WHO) and the Coalition for Innovations in Epidemic Preparedness (Cepi), the Covax system, which aims to provide vaccines this year anti-Covid to 20% of the population of nearly 200 participating countries and territories.
Covax had already signed an agreement with the Serum Institute of India (SII) for 200 million doses of AstraZeneca / Oxford or Novavax vaccines, with an option for 900 million additional doses.
Combined with this contract, the new memorandum of understanding signed with Novavax “will allow the Covax Facility to have 1.1 billion doses of the NVX-CoV2373 vaccine candidate against Covid-19,” Gavi said.
This MoU is an essential step in ensuring that the doses will be made available to all countries and economies participating in the Covax mechanism, once the vaccine is approved by the authorities and licensed by the WHO.
This two-dose American vaccine is under continuous review by the European Medicines Agency (EMA), which paves the way for an upcoming application for authorization in the EU. It is a so-called “subunit” vaccine, based on proteins that trigger an immune response, without viruses. Its designers claim that it is 89.3% effective.